Immix Biopharma, Inc. (IMMX): who owns it and who trades it
As of Nov 16, 2026, IMMX insiders reported 2 purchases worth $10K in the last 12 months. The largest buyer was Gabriel S Morris (CFO), with $5.1K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Immix Biopharma
From the latest filingsOverall: more buying than selling. Funds and insiders mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IMMX
109 funds and institutions reported IMMX shares worth $581M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jupiter Topco LLC with 18.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jupiter Topco LLC | 9.78M | 18.47% | $101M | New |
| Saturn V Capital Management LP | 4.66M | 8.80% | $48M | +26% |
| Eventide Asset Management, LLC | 3.89M | 7.35% | $40.1M | +53% |
| State Street Corp | 3.00M | 5.66% | $30.9M | +1462% |
| BlackRock, Inc. | 2.99M | 5.65% | $30.8M | +538% |
| Deep Track Capital, LP | 2.77M | 5.24% | $28.6M | New |
| Vanguard Capital Management LLC | 2.51M | 4.73% | $25.8M | +40% |
| Opaleye Management Inc. | 2.35M | 4.43% | $24.2M | New |
| Millennium Management LLC | 2.07M | 3.90% | $21.3M | +18% |
| UBS Group AG | 1.94M | 3.67% | $20M | +2427% |
| Marshall Wace, LLP | 1.79M | 3.39% | $18.5M | +9% |
| T. Rowe Price Associates | 1.74M | 3.29% | $17.9M | +319% |
| Wellington Management Group LLP | 1.47M | 2.78% | $15.2M | New |
| Great Point Partners LLC | 1.28M | 2.41% | $13.2M | +265% |
| Geode Capital Management, LLC | 1.20M | 2.27% | $12.4M | +159% |
| Velan Capital Investment Management LP | 1.08M | 2.05% | $11.2M | +47% |
| Logos Global Management LP | 1.00M | 1.89% | $10.3M | -18% |
| Bleichroeder LP | 1.00M | 1.89% | $10.3M | No change |
| Franklin Resources Inc | 969,120 | 1.83% | $10M | No change |
| Burkehill Global Management, LP | 544,118 | 1.03% | $5.6M | +85% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IMMX insiders reported $10K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Ilya M Rachman | CEO | Purchase | 746 | $6.67 | $5K | Form 4 |
| Dec 10, 2025 | Gabriel S Morris | CFO | Purchase | 770 | $6.58 | $5.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Gabriel S Morris | CFO, Director | $5.1K | – | Dec 10, 2025 |
| Ilya M Rachman | CEO and Chairman, Director | $5K | – | Dec 10, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMMX short interest
High short interest. 13.4% of IMMX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 250%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.25M IMMX shares were sold short, 13.4% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 9.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.25M | 13.43% | +5% | 1.22M | 9.2 |
| Oct 15, 2026 | 10.71M | 14.97% | +3% | 1.43M | 7.5 |
| Sep 30, 2026 | 10.39M | 14.52% | +8% | 2.03M | 5.1 |
| Sep 15, 2026 | 9.62M | 13.45% | No change | 1.24M | 7.8 |
| Aug 31, 2026 | 9.62M | 13.44% | -7% | 1.64M | 5.9 |
| Aug 14, 2026 | 10.36M | 14.48% | +9% | 1.49M | 7.0 |
| Jul 31, 2026 | 9.49M | 17.92% | +12% | 1.82M | 5.2 |
| Jul 15, 2026 | 8.50M | 16.05% | +8% | 1.84M | 4.6 |
| Jun 30, 2026 | 7.88M | 14.88% | +99% | 2.93M | 2.7 |
| Jun 15, 2026 | 3.97M | 7.49% | -2% | 1.15M | 3.5 |
| May 29, 2026 | 4.03M | 7.62% | +25% | 1.99M | 2.0 |
| May 15, 2026 | 3.22M | 6.08% | +7% | 769,852 | 4.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Immix Biopharma company events
Immix Biopharma filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 30, 2026.
- Sep 30, 2026AnnouncementImmix Biopharma, Inc., a Delaware corporation, entered into an underwriting agreement with J.P. Morgan Securities LLC, pursuant to which the Company agreed to issue and sell, in an underwritten offering, an aggregate of 11,363,637 shares of its common stock, par value $0.0001 per share at a public… Filing
- Sep 29, 2026AnnouncementThe Company announced an update from the Phase 2 NEXICART-2 clinical trial, including positive results of an 89% (40/45) complete response rate across all forty-five relapsed/refractory AL Amyloidosis patients enrolled in the trial, as assessed by an independent review committee. Filing
- Jul 20, 2026AnnouncementRichard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company. Filing
- May 29, 2026VoteReported shareholder vote results. Filing
- May 21, 2026AnnouncementImmix Biopharma, Inc., a Delaware corporation, entered into an underwriting agreement with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule I thereto, pursuant to which the Company agreed to issue and sell, in an underwritten offering, an aggregate of… Filing
- May 21, 2026AnnouncementThe Company announced an update from the Phase 2 NEXICART-2 NXC-201 clinical trial, including that all four MRD-negative relapsed/refractory AL Amyloidosis patients announced by the Company at the ASH 2025 have converted to CR. Of the first 20 patients in NEXICART-2, all MRD-negative patients have… Filing
- Mar 30, 2026AnnouncementThe Company issued a press release announcing that the enrollment for its NEXICART-2 clinical trial of NXC-201 is complete, with topline results expected in Q3 2026. Filing
- Mar 25, 2026AgreementImmix Biopharma, Inc., a Delaware corporation and Citizens JMP Securities, LLC entered into Amendment No. 1 to that certain At The Market Offering Agreement, dated June 3, 2025, pursuant to which the Company may offer and sell, from time to time, at its option, shares of the Company’s common stock… Filing
- Dec 8, 2025AgreementImmix Biopharma, Inc., a Delaware corporation, entered into an underwriting agreement with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule 1 thereto, relating to the issuance and sale of 19,117,646 shares of its common stock, par value $0.0001 per share… Filing
- Dec 8, 2025AnnouncementThe Company announced positive phase 2 NXC-201 results in an oral presentation at the American Society of Hematology’s ASH 2025 Annual Meeting, presented by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center. Filing
- Nov 26, 2025AnnouncementThis Current Report on Form 8-K is being filed solely to file newly dated consents of KMJ Corbin & Company LLP, formerly the independent registered public accounting firm of Immix Biopharma, Inc., and Crowe LLP, currently the independent registered accounting firm of the Company, each dated… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Immix Biopharma financials
Famous investors that hold IMMX
2 of the 50 well-known investors we track reported holding IMMX in their latest 13F filing. The largest position is Ken Griffin's, worth $9.7M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 931,361 | $9.7M | 0.0% | +84% |
| Israel Englander · Millennium Management | Q3 2026 | 865,940 | $9M | 0.0% | -58% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IMMX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.5% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.5% |
Questions about Immix Biopharma, Inc. (IMMX) stock
Who owns the most IMMX stock?
The largest reported owner of Immix Biopharma, Inc. (IMMX) is Jupiter Topco LLC, with 18.5% of the company. In total, 109 funds and institutions reported holding IMMX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are IMMX insiders buying or selling?
In the last 12 months, IMMX insiders reported 2 open-market purchases worth $10K and no sales. The latest trade was on Dec 10, 2025. See every trade.
What is the short interest in IMMX?
As of Oct 30, 2026, 11.25M IMMX shares were sold short, 13.4% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 9.2 trading days (days to cover). See the history.
Which famous investors hold IMMX?
2 of the 50 well-known investors we track reported IMMX in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $9.7M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.